Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
|Articles|January 21, 2022
Pharmacy Clinical Pearl of the Day: Glioblastoma
Author(s)Saro Arakelians, PharmD
Glioblastoma can be very difficult to treat and a cure is often not possible.
Advertisement
Clinical Pearl of the Day: Glioblastoma
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord.
Insight:
- Glioblastoma forms from cells called astrocytes that support nerve cells.
- Glioblastoma can occur at any age but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting, and seizures.
- Glioblastoma, also known as glioblastoma multiforme, can be very difficult to treat and a cure is often not possible.
- Treatments may slow progression of the cancer and reduce signs and symptoms.
- Diagnosis is done by the use of imaging studies, neurological exams, and biopsy.
- Treatment includes surgery, radiation therapy, chemotherapy, tumor treating fields therapy, and targeted drug therapy.
Sources:
Advertisement
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
FDA Approves Phentolamine Eye Drop for Presbyopia in Adults
5